Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Blinded, Placebo-controlled, Multicenter Study of Siltuximab (Anti IL 6 Monoclonal Antibody) in Subjects With High-risk Smoldering Multiple Myeloma
Conditions
Interventions
Siltuximab
Placebo
Locations
40
United States
Chicago, Illinois, United States
Rockville, Maryland, United States
Detroit, Michigan, United States
New York, New York, United States
Kittanning, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Start Date
March 1, 2012
Primary Completion Date
May 12, 2015
Completion Date
August 21, 2019
Last Updated
January 27, 2020
Lead Sponsor
Janssen Research & Development, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions